Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
about
The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noiseNutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity.Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cellsProgress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Mdm2 promotes systemic lupus erythematosus and lupus nephritisInhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.Retinal angiogenesis suppression through small molecule activation of p53An update on computational oral absorption simulation.Physiologically based pharmacokinetic (PBPK) modeling in children.Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer.Management of retinoblastoma in children: current status.Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models.MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.Influence of parameter perturbations on the reachability of therapeutic target in systems with switchings.Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.Performance of a docking/molecular dynamics protocol for virtual screening of nutlin-class inhibitors of Mdmx.Reducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome.
P2860
Q28542661-CECA3E60-8241-47C9-8B11-A745D3B8A50AQ33918015-32F5C7C6-EB8D-4BBE-86C1-AAB779FB70B4Q34422585-48A498B8-E900-4EC6-8247-40F4DA103E74Q35050530-E40A51DB-D689-4305-BDEC-2E06092AE1AAQ35184378-5BB60B8C-EF0A-47B3-BB47-132D723E2BF3Q35706804-ECF5B9FB-9D9F-4CA4-9F2C-DFC9C9B5791EQ35758450-F61950FF-0823-4A22-8AAC-9551C429DAD9Q36132787-4ADE690B-4D85-4356-B757-B2582D5FE8C6Q36359692-F4DF7551-0217-4DC7-B89C-AD990EE762B1Q36378105-11614666-E057-43BC-A526-ACB17F959071Q37200838-6FFE235B-C2AE-49BC-9190-42AD1592C4F7Q37937047-9C64ECB2-F3D6-4AE8-80DC-352A85382582Q38016332-ED408E48-B91B-4188-960D-98C437BAE290Q38066407-351A8821-F03F-489A-BE7A-16A81DDFC01AQ38368017-5030B533-B0D0-4E90-92F7-17FE71DFEA5CQ38836111-F84DA14B-8220-404E-BD08-5A2A98F60AFEQ40682883-6EA9578B-6F75-42BA-B053-AFBF69385A64Q41500740-B1B62BE7-2CD1-4548-8247-A97575B563F1Q47798259-7D40FD23-1E0B-4CCF-B3A3-AC7659CA125CQ50448397-87ACE837-4E3A-480B-A324-03710638752AQ55386099-BC6F2823-E114-4160-81E8-9D9AE25FA0F0
P2860
Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Whole-body physiologically bas ...... enous and oral administration.
@ast
Whole-body physiologically bas ...... enous and oral administration.
@en
Whole-body physiologically bas ...... enous and oral administration.
@nl
type
label
Whole-body physiologically bas ...... enous and oral administration.
@ast
Whole-body physiologically bas ...... enous and oral administration.
@en
Whole-body physiologically bas ...... enous and oral administration.
@nl
prefLabel
Whole-body physiologically bas ...... enous and oral administration.
@ast
Whole-body physiologically bas ...... enous and oral administration.
@en
Whole-body physiologically bas ...... enous and oral administration.
@nl
P2093
P2860
P356
P1476
Whole-body physiologically bas ...... venous and oral administration
@en
P2093
Clinton F Stewart
Fangyi Zhu
Jeremy Mallari
Jiakun Zhang
John C Panetta
Katie Nemeth
Laura Miller
Martine F Roussel
Michael A Dyer
P2860
P356
10.1124/DMD.110.035915
P50
P577
2010-10-14T00:00:00Z